15/11/2019 5:31 pm Welcome to isteroids.com - BLOG

Friday 04, Feb 2011

  Risk of Osteoporosis raised by chemotherapy

Posted By
Pin it Share on Tumblr

Risk of Osteoporosis raised by chemotherapyChemotherapy for lymphoma should be recognized as a risk factor for the development of osteoporosis, according to Dr. Bhaskar Dasgupta in a poster session at the annual meeting of the British Society for Rheumatology.

Dr. Dasgupta, director of rheumatology, Southend Hospital NHS Trust, Westcliff on Sea, England, said patients with lymphoma have greatly improved survival rates because of advances in treatment, but their quality of life may be compromised by long-term complications of chemotherapy.

Osteoporosis is a complication that can result from treatment with alkylating agents and the steroids that are usually given with chemotherapy.

Monday 05, Jul 2010

  Preemies benefit when expectant mothers are administered with steroids

Posted By
Pin it Share on Tumblr

Preemies benefit when expectant mothers are administered with steroidsAccording to a recent study conducted by researchers at the University of Adelaide, expectant mothers who run a risk of delivering babies much before the full term can benefit when administered with steroids.

Expecting mothers administered with daily doses of steroids experience reduced potential breathing difficulties during delivery.

This finding is expected to have implications for helping medical practitioners in treating expectant mothers.

Monday 10, May 2010

  Asthmatic children do not get benefited with Nitric Oxide

Posted By
Pin it Share on Tumblr

Asthmatic children do not get benefited with Nitric OxideThe level of nitric oxide (NO) in the exhaled breath of an asthmatic individual may portend worsening of asthma symptoms besides signifying an imminent attack linked to underlying airway inflammation.

The results were reported in the second issue for January of the American Journal of Respiratory and Critical Care Medicine, a publication of the American Thoracic Society.

Johan C. de Jongste, M.D., Ph.D., at the Erasmus University Medical Center-Sophia Children’s Hospital in the Netherlands, and colleagues randomized 151 children from 15 academic centers and hospitals with mild to moderate asthma during a 30-week monitoring course.

Monday 19, Apr 2010

  Administering multiple steroid doses not helpful for preemies

Posted By
Pin it Share on Tumblr

Administering multiple steroid doses not helpful for preemiesAccording to a study, pregnant women at the risk of preterm delivery and being administered with multiple doses of steroids are at an increased risk of giving birth to babies with low birth weight and a small head circumference.

It is worth noting here that a single dose of corticosteroids has been considered to be the standard form of care since the last many years when it comes to reducing the chances of infant mortality, respiratory distress syndrome and bleeding in the brain. Moreover, repeated doses to women at the risk of preterm birth have been considered to be useful.

Study lead author Dr. Kellie E. Murphy, who is with Mount Sinai Hospital’s Department of Obstetrics and Gynecology, in Toronto, Canada, said that a single steroid dose to women at risk of preterm birth still holds good and these study results would conclusively stop practitioners from giving multiple courses of antenatal corticosteroids.

Monday 19, Oct 2009

  Survival rate increased with Avastin in recurrent glioblastoma affected patients

Posted By
Pin it Share on Tumblr

Survival rate increased with Avastin in recurrent glioblastoma affected patientsAccording to a recent study that was conduced at 11 centers across the country and published in the early online version of the Journal of Clinical Oncology, survival rate gets increased with Avastin in recurrent glioblastoma affected patients. It was revealed during the study that the targeted therapy Avastin, alone or in combination with CPT-11 (chemotherapy drug) can considerably increase progression-free survival times and survival rates in patients with a deadly form of recurrent brain cancer.

Dr. Timothy Cloughesy, director of the Neuro-Oncology Program at UCLA’s Jonsson Comprehensive Cancer Center and senior author of the study said that positive results from Avastin have promoted the FDA to an accelerated approval of Avastin in May 2009 for use in patients with recurrent glioblastomas.

Avastin is an angiogenesis inhibitor that neutralizes VEGF (vascular endothelial growth factor), which is a chemical signal stimulating the growth of new blood vessels and has already been approved for use in metastatic colorectal, breast, and kidney cancers as well as non-small cell lung cancer.